Literature DB >> 1272274

Reassessment of the use of desferrioxamine B in iron overload.

R D Propper, S B Shurin, D G Nathan.   

Abstract

Treatment of transfusion-induced iron overload by daily intramuscular injection of the chelator desferrioxamine has not produced impressive urinary iron excretion. We attempted to augment net iron excretion by altering both the route and quantity of chelator administered. Two ascorbic acid-replete patients excreted a mean of 14.5 mg of iron per 24 hours after a single intramuscular injection of 750 mg of desferrioxamine. Excretion increased to a mean of 44.9 mg when this dose was delivered by a continuous 24-hour intravenous infusion. When the intravenous dose of chelator was increased incrementally to as high as 16,000 mg per 24 hours, iron excretion increased up to 180 mg per day. At these high-dose levels, efficiency of binding of iron to chelator was compromised. Constant exposure of the labile iron pool to a chelating agent markedly enhances net iron excretion in splenectomized transfusion-dependent patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1272274     DOI: 10.1056/NEJM197606242942603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

1.  Growth plate injury of the long bones in treated beta-thalassemia.

Authors:  C Orzincolo; P N Scutellari; G Castaldi
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  2006 Association of American Physicians George M. Kober Medal. Introduction of David G. Nathan, MD.

Authors:  Edward J Benz
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 3.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Total management of thalassaemia major.

Authors:  B Modell
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

Review 5.  Current concepts in the management of thalassemia.

Authors:  R S Festa
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

6.  Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis.

Authors:  C Salvarani; R Baricchi; D Lasagni; L Boiardi; R Piccinini; C Brunati; P Macchioni; I Portioli
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

7.  A mathematical model of iron metabolism.

Authors:  P C Franzone; A Paganuzzi; M Stefanelli
Journal:  J Math Biol       Date:  1982       Impact factor: 2.259

8.  Value of serum ferritin estimation in sickle cell anaemia.

Authors:  M A Hussain; L R Davis; M Laulicht; A V Hoffbrand
Journal:  Arch Dis Child       Date:  1978-04       Impact factor: 3.791

9.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

10.  High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.

Authors:  H Breithaupt; H Heckers; H Pralle; W Guttmann; H Bleyl; V Graef; G Jundt
Journal:  Blut       Date:  1986-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.